FOR US HEALTHCARE PROFESSIONALS ONLY
FOR US HEALTHCARE PROFESSIONALS ONLY
Go to Patient/Caregiver Site
Instructions for Use Prescribing Information Chiesi Total Care Go to Patient/Caregiver Site
Brand Mobile Logo
Request More Information Butterflies
Home hero Home hero
Henry, FILSUVEZ patient, is a paid spokesperson for Chiesi. This is Henry's personal experience. Your patient's experience may differ.
The only FDA-approved treatment in both dystrophic and junctional epidermolysis bullosa (EB)1

Expanding the possibilities

Choose FILSUVEZ as a core part of your dystrophic or junctional EB wound care plan1
Get your patient started with FILSUVEZ

FILSUVEZ is proven to deliver significant wound closure by Day 45, with1,2:

icon 1 icon-mobile 1
Improvements sustained
through 2 years3
Clinical trial results
icon 2 icon-mobile 2
A tolerable safety profile1
Safety and tolerability
icon 3 icon-mobile 3
Application to every wound, at every wound dressing change1*
Dosing and application
For your patient to be eligible, you must first submit a prescription for FILSUVEZ to the specialty pharmacy

Comprehensive support with Chiesi Total CareSM

Chiesi Total Care helps families start FILSUVEZ, streamlines access, and provides ongoing support throughout the FILSUVEZ treatment journey
Explore Chiesi Total Care
*FILSUVEZ is for dystrophic and junctional EB wounds.1

Important Safety Information & Indication

Important Safety Information

Warnings & Precautions

Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.

Adverse Reactions

The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).

Patient Counseling Information

Please refer to Prescribing Information for administration instructions.

To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Indication

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.

Important Safety Information & Indication

Important Safety Information

Warnings & Precautions

Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.

Adverse Reactions

The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).

Patient Counseling Information

Please refer to Prescribing Information for administration instructions.

To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Indication

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.
References:
1. FILSUVEZ (birch triterpenes) topical gel [prescribing information]. Chiesi USA; 2024.
2. Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol. 2023;188(1):12-21.
3. Murrell D, Bodemer C, Bruckner AL , et al; on behalf of the EASE investigators. Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the phase III EASE study. Br J Dermatol. 2025;192(6):1007-1017.

PP-RA-01341 V1.0